Patrick Wood
Stock Analyst at Morgan Stanley
(4.25)
# 604
Out of 4,412 analysts
53
Total ratings
55%
Success rate
17.22%
Average return
Main Sectors:
19 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SOLV Solventum | Initiates: Equal-Weight | $70 | $64.43 | +8.65% | 1 | Apr 10, 2024 | |
| SWAV ShockWave Medical | Downgrades: Equal-Weight | $285 → $335 | $330.00 | +1.52% | 6 | Apr 8, 2024 | |
| EW Edwards Lifesciences | Maintains: Overweight | $95 → $103 | $86.43 | +19.17% | 6 | Mar 21, 2024 | |
| GEHC GE HealthCare Technologies | Maintains: Equal-Weight | $74 → $86 | $86.24 | -0.28% | 5 | Feb 12, 2024 | |
| DXCM DexCom | Maintains: Equal-Weight | $101 → $122 | $124.34 | -1.88% | 4 | Dec 4, 2023 | |
| BSX Boston Scientific | Maintains: Overweight | $58 → $61 | $73.17 | -16.63% | 2 | Dec 4, 2023 | |
| STE STERIS | Maintains: Equal-Weight | $225 → $215 | $203.90 | +5.44% | 3 | Dec 4, 2023 | |
| RBOT Vicarious Surgical | Initiates: Equal-Weight | $0.6 | $0.27 | +122.22% | 1 | Dec 4, 2023 | |
| GKOS Glaukos | Initiates: Equal-Weight | $65 | $99.48 | -34.66% | 1 | Dec 4, 2023 | |
| STAA STAAR Surgical Company | Initiates: Equal-Weight | $35 | $46.89 | -25.36% | 1 | Dec 4, 2023 | |
| COO The Cooper Companies | Maintains: Equal-Weight | $103 → $89 | $88.84 | -0.10% | 3 | Dec 4, 2023 | |
| BDX Becton, Dickinson and Company | Maintains: Overweight | $310 → $280 | $231.55 | +20.92% | 3 | Dec 4, 2023 | |
| BAX Baxter International | Maintains: Equal-Weight | $45 → $39 | $40.13 | -2.82% | 2 | Dec 4, 2023 | |
| BLCO Bausch + Lomb | Maintains: Equal-Weight | $17 → $16 | $14.79 | +8.18% | 4 | Dec 4, 2023 | |
| PODD Insulet | Upgrades: Overweight | $185 → $234 | $166.19 | +40.80% | 4 | Dec 4, 2023 | |
| TFX Teleflex | Upgrades: Overweight | n/a | $206.71 | - | 3 | Dec 4, 2023 | |
| RXST RxSight | Initiates: Overweight | $36 | $52.77 | -31.78% | 1 | Dec 4, 2023 | |
| ALC Alcon | Downgrades: Underweight | $65 | $78.77 | -17.48% | 2 | Dec 4, 2023 | |
| DVA DaVita | Upgrades: Buy | n/a | $133.51 | - | 1 | Dec 11, 2017 |
Solventum
Apr 10, 2024
Initiates: Equal-Weight
Price Target: $70
Current: $64.43
Upside: +8.65%
ShockWave Medical
Apr 8, 2024
Downgrades: Equal-Weight
Price Target: $285 → $335
Current: $330.00
Upside: +1.52%
Edwards Lifesciences
Mar 21, 2024
Maintains: Overweight
Price Target: $95 → $103
Current: $86.43
Upside: +19.17%
GE HealthCare Technologies
Feb 12, 2024
Maintains: Equal-Weight
Price Target: $74 → $86
Current: $86.24
Upside: -0.28%
DexCom
Dec 4, 2023
Maintains: Equal-Weight
Price Target: $101 → $122
Current: $124.34
Upside: -1.88%
Boston Scientific
Dec 4, 2023
Maintains: Overweight
Price Target: $58 → $61
Current: $73.17
Upside: -16.63%
STERIS
Dec 4, 2023
Maintains: Equal-Weight
Price Target: $225 → $215
Current: $203.90
Upside: +5.44%
Vicarious Surgical
Dec 4, 2023
Initiates: Equal-Weight
Price Target: $0.6
Current: $0.27
Upside: +122.22%
Glaukos
Dec 4, 2023
Initiates: Equal-Weight
Price Target: $65
Current: $99.48
Upside: -34.66%
STAAR Surgical Company
Dec 4, 2023
Initiates: Equal-Weight
Price Target: $35
Current: $46.89
Upside: -25.36%
The Cooper Companies
Dec 4, 2023
Maintains: Equal-Weight
Price Target: $103 → $89
Current: $88.84
Upside: -0.10%
Becton, Dickinson and Company
Dec 4, 2023
Maintains: Overweight
Price Target: $310 → $280
Current: $231.55
Upside: +20.92%
Baxter International
Dec 4, 2023
Maintains: Equal-Weight
Price Target: $45 → $39
Current: $40.13
Upside: -2.82%
Bausch + Lomb
Dec 4, 2023
Maintains: Equal-Weight
Price Target: $17 → $16
Current: $14.79
Upside: +8.18%
Insulet
Dec 4, 2023
Upgrades: Overweight
Price Target: $185 → $234
Current: $166.19
Upside: +40.80%
Teleflex
Dec 4, 2023
Upgrades: Overweight
Price Target: n/a
Current: $206.71
Upside: -
RxSight
Dec 4, 2023
Initiates: Overweight
Price Target: $36
Current: $52.77
Upside: -31.78%
Alcon
Dec 4, 2023
Downgrades: Underweight
Price Target: $65
Current: $78.77
Upside: -17.48%
DaVita
Dec 11, 2017
Upgrades: Buy
Price Target: n/a
Current: $133.51
Upside: -